학술논문
2022台灣腦中風學會非心因性急性缺血中風的抗血小板藥物治療更新指引 / 2022 Focus Update of the 2020 Taiwan Stroke Society Guideline on Antiplatelet Therapy for Noncardioembolic Acute Ischemic Stroke
Document Type
Article
Author
湯頌君 / Sung-Chun Tang; 鍾芷萍 / Chih-Ping Chung; 陳柏霖 / Po-Lin Chen; 李孟 / Meng Lee; 宋碧姍 / Pi-Shan Sung; 劉崇祥 / Chung-Hsiang Liu; 陳右緯 / Yu-Wei Chen; 林雅如 / Ya-Ju Lin; 連立明 / Li-Ming Lien; 張谷州 / Ku-Chou Chang; 李俊泰 / Jiunn-Tay Lee; 鄭建興 / Jiann-Shing Jeng; 非心因性缺血性腦中風抗血小板藥物治療指引共識小組 / Taiwan Stroke Society Guideline Consensus Group
Source
台灣中風醫誌 / Formosan Stroke Journal. Vol. 4 Issue 2, p53-60. 8 p.
Subject
Language
繁體中文
ISSN
2664-1976
Abstract
In 2020, the Taiwan Stroke Society (TSS) published the guideline on antiplatelet therapy for noncardioembolic ischemic stroke. The content of the guideline covered three major topics for the timing and optimal antiplatelet treatment strategy in secondary prevention, acute management, and primary prevention for noncardioembolic ischemic stroke. Nevertheless, new trials related to the use of dual antiplatelet therapy (DAPT) in patients with minor stroke or high risk transient ischemic stroke (TIA) have been published and the analytic results may substantially change the clinical practice. Therefore, an update focusing on the dual antiplatelet therapy in this specific population is necessary. This focused update of the 2020 guideline was made based on the scientific evidence and endorsed by the TSS Guideline Consensus Group. It addressed three major topics including the timing of initiating DAPT after stroke or TIA, combing ticagrelor and aspirin in patients with mild to moderate ischemic stroke or high-risk TIA and treatment strategy in patients carrying CYP2C19 loss of function allele. The reviews of the literatures and recommendations are provided in the manuscript.